-
Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James
Thursday, March 8, 2018 - 2:06pm | 417Read More...Diagnostic healthcare products manufacturer Quidel Corporation (NASDAQ: QDEL)'s shares are not fully reflecting the company's growth potential and likely positive estimate revision bias, according to Raymond James. The Analyst Raymond James analyst Nicholas Jansen upgraded shares...
-
Raymond James Sees 'Lingering Risks' At OraSure, Downgrades To Market Perform
Monday, June 13, 2016 - 10:11am | 303Read More...Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) are up 20 percent year-to-date. Raymond James’ Nicholas Jansen downgraded the rating for the company from Outperform to Market Perform, saying the shares were within 3 percent of the previous price target of $8. Factors Driving...
-
Raymond James Upgrades Quidel To Outperform, Sees New Product Catalysts
Monday, June 13, 2016 - 9:48am | 264Read More...The weak 2015-2016 flu season is now over; and Quidel Corporation (NASDAQ: QDEL) has multiple new product catalysts over the next nine months, Raymond James’ Nicholas Jansen said in a report. He upgraded the rating for the company from Market Perform to Outperform, while establishing a...
